Company / Accounts Receivable
Anixa Biosciences Inc Accounts Receivable History
FY2014-FY2014 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$400.0K
FY2014
5-year range
-
FY2014-FY2014
Trend
-
vs FY2013
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$400,000 in FY2014.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | $400.0K | - |
As of FY2014 · SEC 10-K · Updated Jun 24, 2026